Fair enough.

My experience is that the company that takes the road everyone believed was not going to work...that company is the one that wins out.  In other words, conventional wisdom is generally wrong.

With RVX, we have a small molecule that is turning out to impact multiple pathways at the same time.  We also know that cardiovascular and renal diseases are regulated by multiple pathways of risk.  So Apabetalone, by simultaneously modulating several processes, has the best chance to deliver on what we all hope.  The fact that there has been zero safety issues with this drug, makes me that much more relaxed...no liver issues to worry about!

The reason I think the medical profession has so far failed to get behind RVX, is because it upsets the conventional wisdom on medical research.  A seasoned medical researcher is used to thinking of a single molecular target for a single downstream effect.  The idea that a simple molecule can concurrently modulate multiple biological processes, is effectively telling our seasoned researcher that he/she has been going down the wrong research road all his/her career.  That is a very hard one for any human being to accept.